Gold-standard evidence hub

Type I interferon in lupus

A replicated molecular state and validated treatment target, with important heterogeneity and unresolved biomarker-selection questions.

Inspect claims Read the method

One-minute summary

An interferon-inducible blood gene signature is elevated in a substantial, but not universal, subgroup of people with active SLE.
Blocking the shared type I interferon receptor produced a positive BICLA primary result in TULIP-2, while TULIP-1 did not meet its SRI-4 primary endpoint.
This mixed phase 3 record supports clinical pathway relevance while showing that outcome definition and trial design materially affect interpretation.
A binary high-versus-low blood signature is not a validated stand-alone rule for diagnosis or selection of treatment responders.

What we still do not know

Which upstream nucleic-acid sensors and cell sources dominate interferon activity in each person and organ
Whether longitudinal, continuous, or tissue-specific interferon measures can reproducibly predict flares or treatment response
How blood interferon state maps to kidney, skin, vascular, and central-nervous-system activity
Which non-interferon pathways explain active disease in IFN-low states or nonresponse despite IFN-high status
Long-term comparative effectiveness and uncommon safety outcomes across modern treatment choices

Safety boundary

Interferon-pathway biomarkers are not self-treatment tools. Anifrolumab is prescription biologic therapy with infection, vaccination, hypersensitivity, and population-specific considerations described in its current label.

Claim-level evidence

What each source supports—and what it does not

Every card distinguishes patient outcomes, human mechanisms, models, and site inference.

The molecular state

What a blood interferon signature shows—and what it cannot show.

Human mechanistic evidenceVerified 2026-07-10

An interferon-inducible blood gene-expression pattern is present in a substantial SLE subgroup

Many—but not all—people with active lupus have a high blood-gene pattern associated with type I interferon activity. This is a pathway signal, not a complete explanation of lupus or a stand-alone diagnostic test.

Evidence design: Human Mechanistic + Randomized Controlled Trial
Directness: Human Mechanism

Inspect the evidence

Technical interpretation

Peripheral-blood transcriptomic studies identified an interferon-inducible gene-expression cluster in a subset of SLE samples. In the pooled phase 3 anifrolumab program, most enrolled participants were IFN-signature-high, while a distinct IFN-signature-low group remained, demonstrating molecular heterogeneity within clinically active SLE.

Evidence and provenance

SupportsBaechler et al., PNAS (2003) (opens in a new tab)
Primary human discovery study of the peripheral-blood interferon-inducible signature.
QualifiesMorand et al., New England Journal of Medicine (2020) (opens in a new tab)
Prespecified IFN-high and IFN-low strata show that active SLE is not uniformly signature-high.

Limitations

Whole-blood expression can differ from pathway activity in kidney, skin, brain, and lymphoid tissue
Assay genes, cut points, sample handling, medication, infection, and ancestry can alter classification
The signature is an indirect pathway readout and is not specific to SLE

Review state: Citation Audited · Record ID: ifn-blood-signature-subgroup

Emerging / preliminaryVerified 2026-07-10

Baseline interferon-signature status is not a validated binary treatment-selection rule

A high interferon signature may describe biology, but current trial data do not justify using a simple high-versus-low result to guarantee or rule out response to interferon blockade.

Evidence design: Randomized Controlled Trial
Directness: Validated Surrogate

Inspect the evidence

Technical interpretation

TULIP-2 reported anifrolumab-placebo BICLA differences in both IFN-high and the much smaller IFN-low strata, while TULIP-1 did not show a significant SRI-4 difference in its IFN-high subgroup. These results do not validate baseline binary IFN-gene-signature status as a stand-alone predictive biomarker.

Evidence and provenance

ContradictsMorand et al., New England Journal of Medicine (2020) (opens in a new tab)
Observed responses in the IFN-low stratum contradict a simple claim that only IFN-high participants can respond, although the low subgroup was small.
QualifiesFurie et al., Lancet Rheumatology (2019) (opens in a new tab)
The IFN-high subgroup did not meet the prespecified SRI-4 secondary endpoint in TULIP-1.
QualifiesBaechler et al., PNAS (2003) (opens in a new tab)
The discovery study established association, not prospective treatment-selection performance.

Limitations

The IFN-low trial subgroup was small and confidence intervals are consequently wide
A continuous, dynamic, tissue-specific, or multi-marker assay could perform differently from a binary blood signature
This is a boundary on biomarker interpretation, not evidence that interferon state is clinically irrelevant

Review state: Citation Audited · Record ID: ifn-signature-not-binary-selector

Clinical target validation

Positive and null prespecified phase 3 findings held together.

Supported clinical evidenceVerified 2026-07-10

Type I interferon receptor blockade produced discordant primary-endpoint results across two phase 3 SLE trials

One major anifrolumab trial met its main composite response endpoint; a closely related trial did not meet its different main endpoint. Together they support the pathway as clinically relevant while warning against describing the evidence as uniformly positive.

Evidence design: Randomized Controlled Trial
Directness: Clinical Outcome

Inspect the evidence

Technical interpretation

TULIP-2 reported week-52 BICLA response in 47.8% with anifrolumab versus 31.5% with placebo. TULIP-1 did not meet its week-52 SRI-4 primary endpoint: 36% versus 40%, respectively. Endpoint choice and restricted-medication rules contributed to interpretive complexity but do not erase the prespecified null result.

Evidence and provenance

SupportsMorand et al., New England Journal of Medicine (2020) (opens in a new tab)
Positive prespecified BICLA primary endpoint in TULIP-2.
ContradictsFurie et al., Lancet Rheumatology (2019) (opens in a new tab)
TULIP-1 did not meet its prespecified SRI-4 primary endpoint and bounds any claim of uniform phase 3 efficacy.

Limitations

BICLA and SRI-4 are different composite outcomes and cannot be treated as interchangeable
Both studies tested add-on therapy in selected trial populations over one year
Neither individual trial determines effectiveness for every organ domain or patient subgroup

Review state: Citation Audited · Record ID: ifn-blockade-mixed-phase3

Regulatory and safety boundaries

Current U.S. indication limits and major cautions.

Established careVerified 2026-07-10

The U.S. anifrolumab indication and safety warnings have explicit boundaries

Anifrolumab is FDA-labeled for adults with moderate-to-severe SLE receiving standard therapy, but its label does not recommend it for severe active kidney or central-nervous-system lupus and highlights infection risks.

Evidence design: Guideline Or Regulatory + Randomized Controlled Trial
Directness: Clinical Outcome

Inspect the evidence

Technical interpretation

The April 2026 U.S. label indicates anifrolumab for adults with moderate-to-severe SLE receiving standard therapy. It states that efficacy has not been evaluated in severe active lupus nephritis or severe active CNS lupus and warns about serious infections, including increased respiratory infection and herpes-zoster risk.

Evidence and provenance

DefinesU.S. FDA prescribing information (revised April 2026) (opens in a new tab)
Current primary U.S. source for indication, limitations of use, and warnings.
SupportsMorand et al., New England Journal of Medicine (2020) (opens in a new tab)
Trial report documents the higher herpes-zoster frequency and studied population underlying part of the label evidence.

Limitations

U.S.-specific status and wording can change
Regulatory eligibility is not an individual recommendation
The label should be consulted directly for full contraindications, warnings, administration, and monitoring information

Review state: Citation Audited · Record ID: ifn-label-bounded